Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, CytomX Therapeutics, Inc. (CTMX) has a Wall Street consensus price target of $10.00, based on estimates from 21 covering analysts. With the stock currently trading at $5.37, this represents a potential upside of +86.2%. The company has a market capitalization of $430M.
Analyst price targets range from a low of $10.00 to a high of $10.00, representing a 0% spread in expectations. The median target of $10.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CTMX trades at a trailing P/E of 14.1x. Analysts expect EPS to grow -324.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.45, with bear and bull scenarios of $-36.52 and $5.13 respectively. Model confidence stands at 31/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CTMX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CTMX is $10, representing 86.2% upside from the current price of $5.37. With 21 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CTMX has a consensus rating of "Buy" based on 21 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $10 implies 86.2% upside from current levels.
CTMX's current price is $5.37 with a consensus target of $10 (86.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for CTMX, while the most conservative target is $10. The consensus of $10 represents the median expectation. Our quantitative valuation model projects a bull case target of $5 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CTMX is well covered by analysts, with 21 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CTMX stock forecast based on 21 Wall Street analysts shows a consensus price target of $10, with estimates ranging from $10 (bear case) to $10 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $8, with bear/bull scenarios of $-37/$5.
Our quantitative valuation model calculates CTMX's fair value at $8 (base case), with a bear case of $-37 and bull case of $5. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 31/100.
Wall Street analysts are very optimistic on CTMX, with a "Buy" consensus rating and $10 price target (86.2% upside). 15 of 21 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CTMX analyst price targets range from $10 to $10, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10 consensus represents the middle ground. Our model's $-37-$5 range provides an independent fundamental perspective.